{"pageContent": "Background: Phosphodiesterase type 5 inhibitor (PDE5i) use is common for management of erectile dysfunction. Single-institution studies have reported conflicting data on the relationship between PDE5i use and biochemical recurrence of prostate cancer (BCR) after radical prostatectomy.", "metaData": {"source": "Editorial comment on: Erectile function in prostate cancer-free patients who underwent prostate saturation biopsy\nhttps://pubmed.ncbi.nlm.nih.gov/17619079/"}}